FDA Approves First mRNA Flu Shot, Marks New Era in Vaccine Development The U.S. Food and Drug Administration (FDA) has approved the first influenza vaccine utilizing mRNA technology, known as mFlusiva, developed by biotechnology company Moderna. This marks a significant milestone in vaccine innovation, as the FDA granted conditional approval for the vaccine to be used in adults aged 50 to 65 and those 65 years and older. However, the approval comes with a critical condition: Moderna must conduct an additional clinical trial in the older age group to further evaluate the vaccine’s safety and efficacy. The approval was based on data from a late-stage clinical trial involving over 40,000 participants across 11 countries, including the United States. In this trial, mFlusiva demonstrated an effectiveness rate of approximately 27% higher than the standard flu shot. This finding has sparked optimism among scientists and public health officials, who have long advocated for mRNA-based vaccines due to their potential to revolutionize vaccine development. Unlike traditional flu vaccines, which require months to produce, mRNA vaccines can be manufactured more quickly, enabling researchers to adapt to evolving influenza strains with greater agility. Moderna claims its process takes two to three months from strain selection to vaccine distribution, compared to the six-month timeline for conventional flu shots. The mRNA platform, which was instrumental in the development of the COVID-19 vaccines by Moderna and Pfizer, allows for rapid genetic sequencing and production. This capability is particularly valuable in the context of influenza, which undergoes frequent mutations, making it challenging to create vaccines that remain effective over time. Dr.#fda #robert_f_kennedy_jr #moderna #mflusiva #boston_childrens_hospital
